Please login to the form below

Not currently logged in
Email:
Password:

Renvela

This page shows the latest Renvela news and features for those working in and with pharma, biotech and healthcare.

Sanofi warns of difficult few months as diabetes sales slump

Sanofi warns of difficult few months as diabetes sales slump

The loss of patent protection for kidney disease drug Renvela/Renagel (sevelamer) also took its toll, according to chief executive Olivier Brandicourt, the architect of the turnaround plan at Sanofi, who

Latest news

  • Generic competition for Sanofi's Renvela hits UK market Generic competition for Sanofi's Renvela hits UK market

    Generic competition for Sanofi's Renvela hits UK market. Teva and others launch cheaper versions of the chronic kidney disease drug. ... That was the exception however as most of the drugs, as with Renvela, saw primary care spending in England in the

  • Genzyme wins Scottish approval for Renvela

    Genzyme wins Scottish approval for Renvela. Genzyme UK can supply Renvela within NHS Scotland after securing Scottish Medicine Consortium approval. ... Renvela is a medication for the control of serum phosphorous in patients with CKD.

  • PM Society Advertising Awards 2010

    Digital Media. Renvela by Langland on behalf of Genzyme. Digital Pioneer. Gary Monk.

  • Trials and tribulations

    Sevelamer carbonate. Renvela (Genzyme Corporation). Hypophosphataemia. US. Hydrocodone/ibuprofen. Ibudone (ProEthic Pharmaceuticals).

  • News in brief, May 02, 2007

    The Waterford site will also produce Genzyme's future products, including Tolevamer (GT160-246), a non-antibiotic toxin-binding polymer for the treatment of Clostridium difficile-associated diarrhoea (CDAD) and Renvela,

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics